Psilocybin Trial Shows Anhedonia Gains in Depression
A small randomized trial at the University of Colorado Anschutz found higher-dose psilocybin improved anhedonia at eight weeks in treatment-resistant depression.
Updated on Nov. 18, 2026 in Health

Live Poll
Should psilocybin be pursued as a depression treatment, despite preliminary evidence?
Researchers at the University of Colorado Anschutz reported that a 25-milligram dose of psilocybin, given with psychological support, produced significantly greater improvement in anhedonia than a 1-milligram dose after eight weeks among 20 people with treatment-resistant major depressive disorder. The randomized, double-blind study was published in the Journal of Affective Disorders.
Why it matters
Anhedonia, the loss of ability to feel pleasure, is a core symptom that is often hard to treat in people who have not responded to standard antidepressants. The findings add early evidence for psilocybin as a possible option for this group, with implications for research and clinical care across Colorado, where the study was conducted.
The trial enrolled 20 people with treatment-resistant major depressive disorder and compared 25 milligrams against 1 milligram of psilocybin, with the anhedonia gap appearing only at eight weeks. Whether the benefit lasts beyond that window has not been established.
The players
University of Colorado Anschutz
A health sciences campus of the University of Colorado system in Aurora, Colorado, known for its medical school and psychiatric research programs.
The details
Participants were randomly assigned to receive either 25 milligrams or 1 milligram of psilocybin alongside psychological support. The higher-dose group also showed greater improvement in overall depression severity at one and eight weeks.
Timeline
One week after treatment: no significant difference between groups on the primary anhedonia measure.
Eight weeks after treatment: significant anhedonia improvement in the 25-milligram group.
November 18, 2026: article published on the psilocybin anhedonia study.
Roadmap
The study adds to a growing body of psilocybin trials for treatment-resistant depression, such as those led by Johns Hopkins and NYU Langone, by focusing on anhedonia and comparing dose levels. It is a small study, so its results are best read as an early signal guiding larger trials.
For people with treatment-resistant depression, this research signals a possible future option but not a current treatment, since psilocybin is not yet an approved therapy for this condition. Anyone considering a change in care should talk with a licensed clinician about available options.
The takeaway
Early trial results point to psilocybin as a possible tool for anhedonia, but the evidence is limited to 20 participants. Larger studies will determine whether these benefits hold up over time.
Further reading
For related coverage, see Mental Health reporting on treatment options for depression.
Source note: This article includes information reported by Technology Networks.
Live Poll
Should psilocybin be pursued as a depression treatment, despite preliminary evidence?






